PDF(Pubmed)
Abstract：
UNASSIGNED: To evaluate the clinical efficacy and safety of baloxavir marboxil tablets in the treatment of influenza A.
UNASSIGNED: According to a random sequence generated by computer software, 200 patients with confirmed influenza A were divided into a study group and a control group with 100 cases in each group. Group allocation was concealed using sealed envelopes. The study group was treated with oral administration of baloxavir marboxil tablets, 40 mg once. The control group was given oral oseltamivir capsules, 75 mg twice a day, for five consecutive days. The therapeutic effects, symptom disappearance time and adverse drug reactions of the two groups after 5 days of treatment were compared.
UNASSIGNED: There was no significant difference in the total effective rate between the two groups (99% vs. 98%, p > 0.05). There was no significant difference in fever subsidence time (1.54 ± 0.66 d vs. 1.67 ± 0.71 d, p > 0.05), cough improvement time (2.26 ± 0.91 d vs. 2.30 ± 0.90 d, p > 0.05) and sore throat improvement time (2.06 ± 0.86 d vs. 2.09 ± 0.83 d, p > 0.05) between the two groups. There was no significant difference in the incidence of adverse drug reactions between the two groups (8% vs. 13%, p > 0.05).
UNASSIGNED: Baloxavir marboxil tablets can be effectively used in the treatment of patients with influenza A and have a similar efficacy and safety profile as oseltamivir capsules.
UNASSIGNED: According to a random sequence generated by computer software, 200 patients with confirmed influenza A were divided into a study group and a control group with 100 cases in each group. Group allocation was concealed using sealed envelopes. The study group was treated with oral administration of baloxavir marboxil tablets, 40 mg once. The control group was given oral oseltamivir capsules, 75 mg twice a day, for five consecutive days. The therapeutic effects, symptom disappearance time and adverse drug reactions of the two groups after 5 days of treatment were compared.
UNASSIGNED: There was no significant difference in the total effective rate between the two groups (99% vs. 98%, p > 0.05). There was no significant difference in fever subsidence time (1.54 ± 0.66 d vs. 1.67 ± 0.71 d, p > 0.05), cough improvement time (2.26 ± 0.91 d vs. 2.30 ± 0.90 d, p > 0.05) and sore throat improvement time (2.06 ± 0.86 d vs. 2.09 ± 0.83 d, p > 0.05) between the two groups. There was no significant difference in the incidence of adverse drug reactions between the two groups (8% vs. 13%, p > 0.05).
UNASSIGNED: Baloxavir marboxil tablets can be effectively used in the treatment of patients with influenza A and have a similar efficacy and safety profile as oseltamivir capsules.
摘要：
■根据计算机软件产生的随机序列，评估巴洛沙韦治疗甲型流感的临床疗效和安全性。
■将200例确诊的甲型流感患者分为研究组和对照组,每组100例。使用密封的信封隐藏了小组分配。研究组口服巴洛沙韦，40毫克一次。对照组口服奥司他韦胶囊,每天两次75毫克，连续五天。治疗效果，比较两组患者治疗5d后症状消失时间及药物不良反应。
■两组总有效率无显著差异（99%vs.98%,p>0.05)。退热时间无显著差异（1.54±0.66d与1.67±0.71d，P>0.05)，咳嗽改善时间(2.26±0.91dvs.2.30±0.90d，p>0.05）和咽喉痛改善时间（2.06±0.86dvs.2.09±0.83d，两组之间p>0.05)。两组药物不良反应发生率无显著差异(8%vs.13%,p>0.05)。
■Baloxavirmarboxil片剂可有效用于治疗甲型流感患者，并具有与奥司他韦胶囊相似的疗效和安全性。
■将200例确诊的甲型流感患者分为研究组和对照组,每组100例。使用密封的信封隐藏了小组分配。研究组口服巴洛沙韦，40毫克一次。对照组口服奥司他韦胶囊,每天两次75毫克，连续五天。治疗效果，比较两组患者治疗5d后症状消失时间及药物不良反应。
■两组总有效率无显著差异（99%vs.98%,p>0.05)。退热时间无显著差异（1.54±0.66d与1.67±0.71d，P>0.05)，咳嗽改善时间(2.26±0.91dvs.2.30±0.90d，p>0.05）和咽喉痛改善时间（2.06±0.86dvs.2.09±0.83d，两组之间p>0.05)。两组药物不良反应发生率无显著差异(8%vs.13%,p>0.05)。
■Baloxavirmarboxil片剂可有效用于治疗甲型流感患者，并具有与奥司他韦胶囊相似的疗效和安全性。
